
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NVX-COV2373,COVID-19 Vaccine, Adjuvanted,Matrix-m1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Novavax
Deal Size : Undisclosed
Deal Type : Agreement
Baxter BioPharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine
Details : Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant.
Product Name : Nuvaxovid
Product Type : Vaccine
Upfront Cash : Undisclosed
January 21, 2021
Lead Product(s) : NVX-COV2373,COVID-19 Vaccine, Adjuvanted,Matrix-m1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Novavax
Deal Size : Undisclosed
Deal Type : Agreement
